Outcome (alpha) | Mean (95% CI) | |||||||
---|---|---|---|---|---|---|---|---|
Baseline | Endline | 3-month follow-up | ||||||
EASE (N = 35) | ETAU (N = 32) | EASE (N = 35) | ETAU (N = 32) | d | EASE (N = 35) | ETAU (N = 32) | d | |
PSC (α = 0.87) | 19.3 (14.5, 24.1) | 24.1 (17.6, 30.7) | 20.6 (15.8, 25.4) | 26.0 (19.4, 35.6) | -0.06 | 20.8 (16.0, 25.6) | 22.9 (20.4, 33.5) | -0.13 |
K6* (α = 0.80) | 20.8 (18.8, 22.8) | 20.3 (18.2, 22.4) | 20.0 (18.0, 22.0) | 21.5 (19.4, 23.6) | -0.34 | 20.9 (18.8, 22.9) | 19.9 (17.8, 22.0) | 0.07 |
Alabama-Involvement*^ (α = 0.78) | 31.0 (28.3, 33.7) | 32.0 (29.2, 34.8) | 34.4 (31.7, 37.1) | 35.2 (32.4, 38.0) | 0.02 | 31.7 (29.0, 34.3) | 31.3 (28.5, 34.1) | 0.17 |
Alabama-Positive*^ (α = 0.79) | 22.8 (21.0, 24.5) | 22.9 (21.0, 24.7) | 23.6 (21.8, 25.3) | 23.8 (22.0, 25.6) | -0.01 | 21.9 (20.1, 23.6) | 22.0 (20.2, 23.9) | < 0.01 |
Alabama-Monitoring* (α = 0.69) | 16.3 (14.2, 18.4) | 16.0 (13.5, 18.5) | 18.4 (16.3, 20.5) | 19.1 (16.6, 21.6) | -0.17 | 15.2 (13.0, 17.3) | 14.7 (12.2, 17.2) | 0.03 |
Alabama-Inconsistent* (α = 0.49) | 15.4 (14.0, 16.8) | 17.2 (15.7, 18.6) | 16.2 (14.8, 17.6) | 17.5 (16.1, 19.0) | 0.10 | 14.9 (13.5, 16.3) | 17.4 (15.9, 18.8) | -0.17 |
Alabama-Corporal* (α = 0.65) | 7.7 (6.7, 8.6) | 8.0 (7.0, 9.0) | 7.3 (6.3, 8.2) | 7.5 (6.5, 8.5) | 0.01 | 7.7 (6.8, 8.7) | 8.1 (7.1, 9.1) | -0.02 |